Using the New Biomarkers in Clinical Practice with Dr. Emily Schorr

NfL — neurofilament light, from the blood, not the CSF. Is it a reliable indicator of MS activity, a predictor of relapse-related disability, and a monitor of treatment efficacy? OCT — optical coherence tomography. Fast, safe, reliable, and repeatable, it can reveal the cellular layers inside the retina. But how well does what OCT shows correlate with outcomes of importance in MS? And most important, how can these new biomarkers help clinicians care for their patients with MS now?

Join us, as guest author Dr. Emily Schorr from the Department of Neurosciences at the University of California San Diego, addresses some of these questions in this issue of eMultipleSclerosis Review.